William Ridgway Appointed Director of UC's Division of Immunology
William Ridgway, MD, has been appointed director of the division of immunology at the University of Cincinnati (UC)
Ridgway was previously an associate professor of medicine, with tenure, in the division of rheumatology and clinical immunology at the University of Pittsburgh School of Medicine where he researched the genetics and cellular immunology of autoimmunity. He focuses primarily on investigating mouse models with spontaneous autoimmune syndromes such as type 1 diabetes and autoimmune liver disease. He was also a principal investigator within the National Institutes of Health (NIH) funded Autoimmunity Center of Excellence at the
From 1998 to 2003, Ridgway served as chief of the rheumatology division at the
I am very excited to have Dr. Ridgway lead UCs division of immunology, says David Stern, MD, vice president for health affairs at UC and dean of the
He will be a welcome addition to the leadership team of the
Ridgway received his medical degree from the
He has collaborated with many physicians, nationally and internationally, on basic research, particularly in the areas of autoimmunity and autoimmune phenotypes. Additionally, Ridgway has retained repeated research support through grants from the NIH.
During his career, Ridgway has received several distinguished awards including the
highly competitive Pfizer Scholars Grant for new faculty and Juvenile Diabetes Foundation International Career Development Award. He is a member of the
I am pleased and honored to join the Division of Immunology at University of Cincinnati Academic Health Center, Ridgway says. I look forward to starting new research initiatives in lupus, allergy and the immunogenetics of autoimmune disease.
Ridgway replaces John Houk, MD, interim director of the immunology division.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.